How and why we engage with psychedelic compounds is quickly changing, thanks in large part to a plethora of ongoing medicinal research and shifts in policy. Compounds once known for their recreational use \u2014such as psilocybin and MDMA\u2014 are being closely examined for their potential in various treatments related to mental health. <\/p>\n
Here\u2019s a summary of the latest news regarding research, trials, and advancement of U.S. Food and Drug Administration (FDA) approvals for a number of psychedelic medicines.<\/p>\n
Ketamine is currently being used off-label<\/a> in clinics across the U.S. to help treat mental health conditions and chronic pain.<\/p>\n In 2019, ketamine derivative esketamine (Spravato) was approved by the FDA to be used as an intranasal spray for those with treatment-resistant depression. Since then, there have been more approved clinical trials to examine the efficacy of ketamine for a number of conditions.<\/p>\n Earlier this year, the administration approved PharmaTher, a clinical-stage psychedelics biotech company, in a Phase 2 clinical study with ketamine to treat Parkinson\u2019s disease<\/a>. <\/p>\n In early August, the same company was granted a special status known as \u201corphan drug designation<\/a>,\u201d to research ketamine treatment<\/a> for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig\u2019s disease. <\/p>\n Additional ketamine research was published in the September\/October issue of the Harvard Review of Psychiatry, including a study on ketamine\u2019s impact on various cognitive processes<\/a>. It found that the use of ketamine and esketamine had no adverse effect on memory, attention and other cognitive functions.<\/p>\n \u201cKetamine and esketamine do not seem to exert significant deleterious neurocognitive effects in the short or long term in individuals with treatment-resistant depression. Results suggest neuropsychological functions and brain areas commonly impaired in treatment-resistant depression may especially benefit from subanesthetic ketamine infusions,\u201d the report concludes. <\/p>\n Positive progress has been made in the U.S. related to medicinal applications of psilocybin, which is known colloquially as \u201cmagic mushrooms.\u201d <\/p>\n Last year, Oregon became the first state to approve the legal use of psychedelic mushrooms in licensed facilities<\/a>. Earlier this summer, Texas<\/a> and Connecticut<\/a> followed a similar path, legally approving research into how psilocybin can help people suffering from Post Traumatic Stress Disorder (PTSD). <\/p>\n Toronto-based company Revive Therapeutics <\/a>announced this month that it was entering into FDA clinical studies with psilocybin to test the drug\u2019s impact on those with methamphetamine use disorder and stroke<\/a>. It\u2019s partnered with University of Wisconsin-Madison\u2019s School of Medicine and Public Health and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin.<\/p>\n Meanwhile, Johns Hopkins University\u2019s Center for Psychedelic and Consciousness Research has a host of psilocybin-related studies underway. These include ongoing studies on anorexia nervosa<\/a>, smoking cessation<\/a>, depression<\/a>, and Alzheimer\u2019s Disease<\/a>.<\/p>\n A study published in February looked at a large analysis of various psilocybin studies<\/a> in order to offer guidance on optimal dosing practices of psilocybin.<\/p>\n In July, a study published<\/a> in the New England Journal examined Psilocybin versus Escitalopram, the generic version of Lexapro, an SSRI, for the treatment of depression. It found that \u201csecondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons.\u201d<\/p>\n MDMA, known colloquially as molly or ecstasy, has been subject to research that suggests it can help with various mental health conditions. One organization making huge strides in MDMA research<\/a> is the Multidisciplinary Association for Psychedelic Studies (MAPS). <\/p>\n Researchers at MAPS are working on a plan that would see MDMA-assisted therapy become an FDA-approved, prescribable treatment<\/a> by 2023. The organization released the results of a Phase 3 clinical trial that determined that MDMA-assisted therapy may be a safe and effective treatment for PTSD.<\/p>\n The study, published this year in Nature Medicine<\/a>, found that MDMA brought relief to participants who suffered from PTSD, when the treatment was paired with talk therapy.<\/p>\n MAPS is simultaneously researching whether MDMA-assisted therapy can help heal wounds from psychological and emotional damage caused by sexual assault, war, violent crime, and other traumas. They\u2019ve also sponsored completed studies on MDMA-assisted therapy for autistic adults with social anxiety, and MDMA-assisted therapy for anxiety related to life-threatening illnesses.<\/p>\n In other psychedelic medicine news\u2026<\/p>\n In July, a U.S. House appropriations resolution, HR 4502<\/a>, was passed with secondary guidance<\/a> to contribute funds toward psychedelic research for treatments for PTSD, major depressive disorder, and other mental health conditions. The funding would focus on treatments with \u201cBreakthrough Therapy<\/a>\u201d designation, which allows biotechnology and pharmaceutical companies an expedited review process for experimental drugs that are shown to have treatment advantages over existing therapies for diseases that are difficult to treat.<\/p>\n In late July, biotech company Mind Medicine Inc. launched a Phase 1 clinical research study on DMT<\/a>, colloquially known as the ‘Spirit molecule. The compound has shown to have promising effects on issues like depression and anxiety. <\/p>\nPsilocybin Research, Legislation, and Approval Tracks<\/h2>\n
MDMA Research, Legislation, and Approval Tracks<\/h2>\n
Other Psychedelic Medicine News and Research<\/h2>\n